These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 17131494)
1. Targeting intestinal microflora in inflammatory bowel disease. Guslandi M World J Gastroenterol; 2006 Nov; 12(44):7225-6. PubMed ID: 17131494 [No Abstract] [Full Text] [Related]
2. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Rioux KP; Madsen KL; Fedorak RN Gastroenterol Clin North Am; 2005 Sep; 34(3):465-82, ix. PubMed ID: 16084308 [No Abstract] [Full Text] [Related]
3. [Probiotics and prebiotics for the treatment of inflammatory bowel disease]. Mitsuyama K Nihon Rinsho; 2005 May; 63(5):850-8. PubMed ID: 15881181 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of probiotics in inflammatory bowel disease]. Mitsuyama K Nihon Rinsho; 2012 Feb; 70 Suppl 1():358-64. PubMed ID: 23126118 [No Abstract] [Full Text] [Related]
5. [Role of intestinal flora in inflammatory bowel disease and probiotics place in their management]. Belkahla N; Maamouri N; Ouerghi H; Ben Ammar A Tunis Med; 2005 Mar; 83(3):132-6. PubMed ID: 15929439 [TBL] [Abstract][Full Text] [Related]
6. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Ghosh S; van Heel D; Playford RJ Gut; 2004 May; 53(5):620-2. PubMed ID: 15082574 [No Abstract] [Full Text] [Related]
11. Probiotics and prebiotics in chronic inflammatory bowel diseases. Ewaschuk JB; Dieleman LA World J Gastroenterol; 2006 Oct; 12(37):5941-50. PubMed ID: 17009391 [TBL] [Abstract][Full Text] [Related]
12. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. Cash BD Curr Med Res Opin; 2014 Jul; 30(7):1405-15. PubMed ID: 24666019 [TBL] [Abstract][Full Text] [Related]
13. Promotion of a favorable gut flora in inflammatory bowel disease. Kennedy RJ; Kirk SJ; Gardiner KR JPEN J Parenter Enteral Nutr; 2000; 24(3):189-95. PubMed ID: 10850949 [TBL] [Abstract][Full Text] [Related]
14. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. DuPont HL; Jiang ZD Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005 [TBL] [Abstract][Full Text] [Related]
15. Rifaximin: a nonabsorbed oral antibiotic. Baker DE Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929 [TBL] [Abstract][Full Text] [Related]
16. Existing knowledge of the human gut microbiota. Macfarlane G J Pediatr Gastroenterol Nutr; 2008 Apr; 46 Suppl 1():E10. PubMed ID: 18354313 [No Abstract] [Full Text] [Related]
17. "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. Doman DB; Goldberg HJ; Golding MI Am J Gastroenterol; 2008 Jan; 103(1):251-2. PubMed ID: 18184139 [No Abstract] [Full Text] [Related]
18. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. Andoh A; Fujiyama Y World J Gastroenterol; 2006 Jul; 12(28):4452-60. PubMed ID: 16874854 [TBL] [Abstract][Full Text] [Related]
19. Probiotics and inflammatory bowel diseases. Bai AP; Ouyang Q Postgrad Med J; 2006 Jun; 82(968):376-82. PubMed ID: 16754706 [TBL] [Abstract][Full Text] [Related]
20. Effect of probiotics on intestinal barrier function. Mennigen R; Bruewer M Ann N Y Acad Sci; 2009 May; 1165():183-9. PubMed ID: 19538305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]